Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Nutrients
Special Issues
Bioactive Lipids and Metabolic Disease
nutrients-logo
Submit to Nutrients Review for Nutrients Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Bioactive Lipids and Metabolic Disease

A special issue of Nutrients (ISSN 2072-6643). This special issue belongs to the section "Lipids".

Deadline for manuscript submissions: closed (15 April 2025) | Viewed by 7387

Special Issue Editors

Dr. Zhen Chen

E-Mail Website
Guest Editor
School of Pharmacy, Jiangsu University, Zhenjiang 212013, China
Interests: functional foods; food chemistry; lipid metabolism; oxidative stress; antioxidation; lipid analysis; lipidomics
Special Issues, Collections and Topics in MDPI journals
Dr. Valerie Tikhonoff

E-Mail Website
Guest Editor
Department of Medicine, University of Padua, 35100 Padua, Italy
Interests: nutrition; epidemiology; diet; macro and micronutrients; lipids; hypertension; uric acid; cardiovascular risk factors; cardiovascular prevention; public health; obesity

Special Issue Information

Dear Colleagues,

I am pleased to announce the launch of the Special Issue of Nutrients entitled “Bioactive Lipids and Metabolic Disease”. The complex link between metabolic disorders and lipid metabolism necessitates a deeper understanding of how to regulate our bodies for optimal health through nutritional science. This Special Issue emphasizes the most recent research on bioactive lipids, their regulatory functions in metabolic pathways and potential applications in therapy, along with their intersection with nutritional science to enhance health outcomes.

By assembling this pioneering repository of knowledge, our objective is to connect the dots between lipid biochemistry, metabolic disease research, clinical applications and nutritional insights. We are particularly interested in submissions of original research articles and comprehensive reviews that explore the mechanisms through which bioactive lipids influence metabolic diseases. This includes their identification, functional analysis, interactions with dietary components and consequent effects on health outcomes. Studies elucidating the molecular pathways mediated by bioactive lipids, their contribution to disease prevention and management, and the innovation of lipid-based therapeutics, with an eye toward nutritional interventions, are highly encouraged.

We look forward to your valuable contributions.

Dr. Zhen Chen
Dr. Valerie Tikhonoff
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Nutrients is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bioactive lipids
  • functional food
  • cardiovascular health
  • metabolic syndrome
  • hypolipidemia
  • mitochondrial function
  • non-alcoholic fatty liver disease (NAFLD)
  • obesity prevention
  • lipid therapeutics
  • molecular nutrition
  • dietary lipids and health

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 1110 KiB  
Article
Cholesin mRNA Expression in Human Intestinal, Liver, and Adipose Tissues
by Hannah Gilliam-Vigh, Malte P. Suppli, Sebastian M. N. Heimbürger, Asger B. Lund, Filip K. Knop and Anne-Marie Ellegaard
Nutrients 2025, 17(4), 619; https://doi.org/10.3390/nu17040619 - 8 Feb 2025
Viewed by 1086
Abstract
Objective: Cholesin is a recently discovered gut-derived hormone secreted by enterocytes upon dietary cholesterol uptake via the transmembrane sterol transporter Niemann–Pick disease C1-like intracellular cholesterol transporter 1 (NPC1L1). In the liver, cholesin activates G protein-coupled receptor 146 (GPR146), causing reduced cholesterol synthesis. In [...] Read more.
Objective: Cholesin is a recently discovered gut-derived hormone secreted by enterocytes upon dietary cholesterol uptake via the transmembrane sterol transporter Niemann–Pick disease C1-like intracellular cholesterol transporter 1 (NPC1L1). In the liver, cholesin activates G protein-coupled receptor 146 (GPR146), causing reduced cholesterol synthesis. In this exploratory, hypothesis-generating study based on post hoc analysis, human data on the cholesin system are presented. Methods: Mucosal biopsies were collected throughout the intestinal tract from 12 individuals with type 2 diabetes (T2D) and 12 healthy, matched controls. Upper small intestinal mucosal biopsies were collected from 20 individuals before and after Roux-en-Y gastric bypass (RYGB) surgery. Liver biopsies were collected from 12 men with obesity and 15 matched controls without obesity. Subcutaneous abdominal adipose tissue biopsies were collected from 20 men with type 1 diabetes (T1D). All biopsies underwent full mRNA sequencing. Results: Cholesin mRNA expression was observed throughout the intestinal tracts of the individuals with T2D and the controls, in the livers of men with and without obesity, and in adipose tissue of men with T1D. NPC1L1 mRNA expression was robust throughout the small intestines but negligible in the large intestines of both individuals with and without T2D. RYGB surgery induced the expression of NPC1L1 mRNA in the upper small intestine. GPR146 mRNA was expressed in the livers of men, both with and without obesity, and in the adipose tissue of men with T1D, but not in the intestines. Conclusions: Our results suggest a role of the cholesin system in human physiology, but whether it is perturbed in metabolic diseases remains unknown. Clinical trial registration numbers: NCT03044860, NCT03093298, NCT02337660, NCT03734718. Full article
(This article belongs to the Special Issue Bioactive Lipids and Metabolic Disease)
►▼ Show Figures

Figure 1

14 pages, 4055 KiB  
Article
Alisma Orientalis Extract Ameliorates Hepatic Iron Deregulation in MAFLD Mice via FXR-Mediated Gene Repression
by Yanlin Li, Ke Zhang, Yue Feng, Lei Wu, Yimin Jia and Ruqian Zhao
Nutrients 2024, 16(14), 2272; https://doi.org/10.3390/nu16142272 - 15 Jul 2024
Cited by 2 | Viewed by 1989
Abstract
Iron is a vital trace element for our bodies and its imbalance can lead to various diseases. The progression of metabolic-associated fatty liver disease (MAFLD) is often accompanied by disturbances in iron metabolism. Alisma orientale extract (AOE) has been reported to alleviate MAFLD. [...] Read more.
Iron is a vital trace element for our bodies and its imbalance can lead to various diseases. The progression of metabolic-associated fatty liver disease (MAFLD) is often accompanied by disturbances in iron metabolism. Alisma orientale extract (AOE) has been reported to alleviate MAFLD. However, research on its specific lipid metabolism targets and its potential impact on iron metabolism during the progression of MAFLD remains limited. To establish a model of MAFLD, mice were fed either a standard diet (CON) or a high-fat diet (HFD) for 9 weeks. The mice nourished on the HFD were then randomly assigned to the HF group and the HFA group, with the HFA group receiving AOE by gavage on a daily basis for 13 weeks. Supplementation with AOE remarkably reduced overabundant lipid accumulation in the liver and restored the iron content of the liver. AOE partially but significantly reversed dysregulated lipid metabolizing genes (SCD1, PPAR γ, and CD36) and iron metabolism genes (TFR1, FPN, and HAMP) induced by HFD. Chromatin immunoprecipitation assays indicated that the reduced enrichment of FXR on the promoters of SCD1 and FPN genes induced by HFD was significantly reversed by AOE. These findings suggest that AOE may alleviate HFD-induced disturbances in liver lipid and iron metabolism through FXR-mediated gene repression. Full article
(This article belongs to the Special Issue Bioactive Lipids and Metabolic Disease)
►▼ Show Figures

Graphical abstract

14 pages, 10465 KiB  
Article
Lipidomic Assessment of the Inhibitory Effect of Standardized Water Extract of Hydrangea serrata (Thunb.) Ser. Leaves during Adipogenesis
by Jae Sik Yu, Hee Ju Kim, Yeo Eun Kim, Hyun Ok Yang, Yu-Kyong Shin, Hyunjae Kim, Soyoon Park and Gakyung Lee
Nutrients 2024, 16(10), 1508; https://doi.org/10.3390/nu16101508 - 16 May 2024
Viewed by 1414
Abstract
Obesity is primarily exacerbated by excessive lipid accumulation during adipogenesis, with triacylglycerol (TG) as a major lipid marker. However, as the association between numerous lipid markers and various health conditions has recently been revealed, investigating the lipid metabolism in detail has become necessary. [...] Read more.
Obesity is primarily exacerbated by excessive lipid accumulation during adipogenesis, with triacylglycerol (TG) as a major lipid marker. However, as the association between numerous lipid markers and various health conditions has recently been revealed, investigating the lipid metabolism in detail has become necessary. This study investigates the lipid metabolic effects of Hydrangea serrata (Thunb.) Ser. hot water leaf extract (WHS) on adipogenesis using LC-MS-based lipidomics analysis of undifferentiated, differentiated, and WHS-treated differentiated 3T3-L1 cells. WHS treatment effectively suppressed the elevation of glycerolipids, including TG and DG, and prevented a molecular shift in fatty acyl composition towards long-chain unsaturated fatty acids. This shift also impacted glycerophospholipid metabolism. Additionally, WHS stabilized significant lipid markers such as the PC/PE and LPC/PE ratios, SM, and Cer, which are associated with obesity and related comorbidities. This study suggests that WHS could reduce obesity-related risk factors by regulating lipid markers during adipogenesis. This study is the first to assess the underlying lipidomic mechanisms of the adipogenesis-inhibitory effect of WHS, highlighting its potential in developing natural products for treating obesity and related conditions. Our study provides a new strategy for the development of natural products for the treatment of obesity and related diseases. Full article
(This article belongs to the Special Issue Bioactive Lipids and Metabolic Disease)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

35 pages, 3808 KiB  
Review
Oxylipins Derived from PUFAs in Cardiometabolic Diseases: Mechanism of Actions and Possible Nutritional Interactions
by Duygu Ağagündüz, Özge Yeşildemir, Emine Koçyiğit, Tevfik Koçak, Buket Özen Ünaldı, Gamze Ayakdaş and Ferenc Budán
Nutrients 2024, 16(22), 3812; https://doi.org/10.3390/nu16223812 - 7 Nov 2024
Cited by 1 | Viewed by 2299
Abstract
Oxylipins are oxidized fatty acids, both saturated and unsaturated, formed through pathways that involve singlet oxygen or dioxygen-mediated oxygenation reactions and are primarily produced by enzyme families such as cyclooxygenases, lipoxygenases, and cytochrome P450. These lipid-based complex bioactive molecules are pivotal signal mediators, [...] Read more.
Oxylipins are oxidized fatty acids, both saturated and unsaturated, formed through pathways that involve singlet oxygen or dioxygen-mediated oxygenation reactions and are primarily produced by enzyme families such as cyclooxygenases, lipoxygenases, and cytochrome P450. These lipid-based complex bioactive molecules are pivotal signal mediators, acting in a hormone-like manner in the pathophysiology of numerous diseases, especially cardiometabolic diseases via modulating plenty of mechanisms. It has been reported that omega-6 and omega-3 oxylipins are important novel biomarkers of cardiometabolic diseases. Moreover, collected literature has noted that diet and dietary components, especially fatty acids, can modulate these oxygenated lipid products since they are mainly derived from dietary omega-3 and omega-6 polyunsaturated fatty acids (PUFAs) or linoleic acid and α-linolenic by elongation and desaturation pathways. This comprehensive review aims to examine their correlations to cardiometabolic diseases and how diets modulate oxylipins. Also, some aspects of developing new biomarkers and therapeutical utilization are detailed in this review. Full article
(This article belongs to the Special Issue Bioactive Lipids and Metabolic Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop